Neurotransmitter-based strategies for the treatment of cognitive dysfunction in Down syndrome

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 54, Issue , 2014, Pages 140-148

  Das, Devsmita ^a,c   Phillips, Cristy ^b   Hsieh, Wayne ^a   Sumanth, Krithika ^a   Dang, Van ^a,c   Salehi, Ahmad ^a,c  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b ARKANSAS STATE UNIVERSITY   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Down syndrome; Formoterol; L Dops; Locus coeruleus

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; ATOMOXETINE; DIZOCILPINE; FLUOXETINE; FORMOTEROL; MEMANTINE; NEUROTRANSMITTER; NORADRENALIN; RG 1662; RIVASTIGMINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; THREO 3,4 DIHYDROXYPHENYLSERINE; UNCLASSIFIED DRUG; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS;

ALZHEIMER DISEASE; ASTHMA; ATTENTION DEFICIT DISORDER; AUTONOMIC NERVOUS SYSTEM; BEHAVIOR DISORDER; BLOOD BRAIN BARRIER; CHOLINERGIC SYSTEM; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; DEMENTIA; DEPRESSION; DISEASE EXACERBATION; DOWN SYNDROME; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG PENETRATION; DRUG SAFETY; GABAERGIC SYSTEM; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GLUTAMATERGIC SYSTEM; HEART DISEASE; HIPPOCAMPUS; HUMAN; LEARNING DISORDER; LONG TERM POTENTIATION; LOW DRUG DOSE; MOLECULAR PATHOLOGY; MOUSE MODEL; NERVE CELL NETWORK; NERVE CELL PLASTICITY; NEUROPATHOLOGY; NEUROTRANSMISSION; NONHUMAN; NOREPINEPHRINERGIC SYSTEM; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; RESPIRATORY TRACT DISEASE; REVIEW; RISK BENEFIT ANALYSIS; SEROTONINERGIC SYSTEM; SIGNAL TRANSDUCTION; TRISOMY; ANIMAL; COGNITION DISORDERS; DRUG EFFECTS; GENETICS; PATHOPHYSIOLOGY;

ANIMALS; COGNITION DISORDERS; DOWN SYNDROME; HIPPOCAMPUS; HUMANS; NEUROTRANSMITTER AGENTS;

EID: 84902485883     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2014.05.004     Document Type: Review

References (114)

1. Ahuja N., Easwaran H., Baylin S.B. Harnessing the potential of epigenetic therapy to target solid tumors. J Clin Invest 2014, 124:56-63.
2. Altafaj X., Dierssen M., Baamonde C., Marti E., Visa J., Guimera J., et al. Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome. Hum Mol Genet 2001, 10:1915-1923.
3. Altafaj X., Ortiz-Abalia J., Fernandez M., Potier M.C., Laffaire J., Andreu N., et al. Increased NR2A expression and prolonged decay of NMDA-induced calcium transient in cerebellum of TgDyrk1A mice, a mouse model of Down syndrome. Neurobiol Dis 2008, 32:377-384.
4. Antonarakis S.E. 10years of genomics, chromosome 21, and Down syndrome. Genomics 1998, 51:1-16.
5. Araki T1., Wake R., Miyaoka T., Kawakami K., Nagahama M., Furuya M., et al. The effects of combine treatment of memantine and donepezil on Alzheimer's disease patients and its relationship with cerebral blood flow in the prefrontal area. Int J Geriatr Psychiatry 2014, [in press]. 10.1002/gps.4074.
6. Balse E., Lazarus C., Kelche C., Jeltsch H., Jackisch R., Cassel J.C. Intrahippocampal grafts containing cholinergic and serotonergic fetal neurons ameliorate spatial reference but not working memory in rats with fimbria-fornix/cingular bundle lesions. Brain Res Bull 1999, 49:263-272.
7. Beacher F1., Daly E., Simmons A., Prasher V., Morris R., Robinson C., et al. Brain anatomy and ageing in non-demented adults with Down's syndrome: an in vivo MRI study. Psychol Med 2010, 40:611-619.
8. Belichenko P.V., Masliah E., Kleschevnikov A.M., Villar A.J., Epstein C.J., Salehi A., et al. Synaptic structural abnormalities in the Ts65Dn mouse model of Down Syndrome. J Comp Neurol 2004, 480:281-298.
9. Belichenko P.V., Kleschevnikov A.M., Salehi A., Epstein C.J., Mobley W.C. Synaptic and cognitive abnormalities in mouse models of Down syndrome: exploring genotype-phenotype relationships. J Comp Neurol 2007, 504:329-345.
10. Bell K., Shokrian D., Potenzieri C., Whitaker-Azmitia P.M. Harm avoidance, anxiety, and response to novelty in the adolescent S-100 beta transgenic mouse: role of serotonin and relevance to Down syndrome. Neuropsychopharmacology 2003, 28:1810-1816.
11. Bianchi P., Ciani E., Guidi S., Trazzi S., Felice D., Grossi G., et al. Early pharmacotherapy restores neurogenesis and cognitive performance in the Ts65Dn mouse model for Down syndrome. J Neurosci 2010, 30:8769-8779.
12. Boada R., Hutaff-Lee C., Schrader A., Weitzenkamp D., Benke T.A., Goldson E.J., et al. Antagonism of NMDA receptors as a potential treatment for Down syndrome: a pilot randomized controlled trial. Transl Psychiatry 2012, 2:e141.
13. Boureau Y.L., Dayan P. Opponency revisited: competition and cooperation between dopamine and serotonin. Neuropsychopharmacology 2011, 36:74-97.
14. Capone G., Goyal P., Ares W., Lannigan E. Neurobehavioral disorders in children, adolescents, and young adults with Down syndrome. Am J Med Genet C Semin Med Genet 2006, 1(42C):158-172.
15. Carlini V.P., Poretti M.B., Rask-Andersen M., Chavan R.A., Ponzio M.F., Sawant R.S., et al. Differential effects of fluoxetine and venlafaxine on memory recognition: possible mechanisms of action. Prog Neuropsychopharmacol Biol Psychiatry 2012, 38:159-167.
16. Cataldo A.M., Peterhoff C.M., Troncoso J.C., Gomez-Isla T., Hyman B.T., Nixon R.A. Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am J Pathol 2000, 157:277-286.
17. Chakrabarti L., Best T.K., Cramer N.P., Carney R.S., Isaac J.T., Galdzicki Z., et al. Olig1 and Olig2 triplication causes developmental brain defects in Down syndrome. Nat Neurosci 2010, 13:927-934.
18. Chen T.F., Huang R.F., Lin S.E., Lu J.F., Tang M.C., Chiu M.J. Folic Acid potentiates the effect of memantine on spatial learning and neuronal protection in an Alzheimer's disease transgenic model. J Alzheimers Dis 2010, 20:607-615.
19. Cooper J.D., Salehi A., Delcroix J.D., Howe C.L., Belichenko P.V., Chua-Couzens J., et al. Failed retrograde transport of NGF in a mouse model of Down's syndrome: reversal of cholinergic neurodegenerative phenotypes following NGF infusion. Proc Natl Acad Sci U S A 2001, 98:10439-10444.
20. Coppus A.W1., Fekkes D., Verhoeven W.M., Tuinier S., Egger J.I., van Duijn C.M. Plasma amino acids and neopterin in healthy persons with Down's syndrome. J Neural Transm 2007, 114(8):1041-1045.
21. Cossec J.C., Lavaur J., Berman D.E., Rivals I., Hoischen A., Stora S., et al. Trisomy for synaptojanin1 in Down syndrome is functionally linked to the enlargement of early endosomes. Hum Mol Genet 2012, 21:3156-3172.
22. Costa A.C., Scott-McKean J.J., Stasko M.R. Acute injections of the NMDA receptor antagonist memantine rescue performance deficits of the Ts65Dn mouse model of Down syndrome on a fear conditioning test. Neuropsychopharmacology 2008, 33:1624-1632.
23. Craciunescu C.N1., Johnson A.R., Zeisel S.H. Dietary choline reverses some, but not all, effects of folate deficiency on neurogenesis and apoptosis in fetal mouse brain. J Nutr 2010, 140(6):1162-1166. [2010 Jun].
24. Cramer N., Galdzicki Z. From abnormal hippocampal synaptic plasticity in down syndrome mouse models to cognitive disability in down syndrome. Neural Plast 2012, 2012:101542.
25. Cramer N.P., Best T.K., Stoffel M., Siarey R.J., Galdzicki Z. GABAB-GIRK2-mediated signaling in Down syndrome. Adv Pharmacol 2010, 58:397-426.
26. Dang V., Martin K., Moghadam S., Medina B., Lin B., Patel D., et al. Improving noradrenergic signaling in the treatment of cognitive dysfunction in the Ts65dn mouse model of down syndrome. Poster 348.12/M8 2012.
27. Dang V., Medina B., Das D., Moghadam S., Martin K.J., Lin B., et al. Formoterol, a long-acting β2 adrenergic agonist, improves cognitive function and promotes dendritic complexity in a mouse model of Down syndrome. Biol Psychiatry 2014, 2014(75):179-188.
28. De la Torre R., De Sola S., Pons M., Duchon A., de Lagran M.M., Farré M., et al. Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans. Mol Nutr 2014, 58:278-288.
29. Devauges V., Sara S.J. Memory retrieval enhancement by locus coeruleus stimulation: evidence for mediation by beta-receptors. Behav Brain Res 1991, 43:93-97.
30. Dong H., Yuede C.M., Coughlan C., Lewis B., Csernansky J.G. Effects of memantine on neuronal structure and conditioned fear in the Tg2576 mouse model of Alzheimer's disease. Neuropsychopharmacology 2008, 33:3226-3236.
31. Elroy-Stein O., Groner Y. Impaired neurotransmitter uptake in PC12 cells overexpressing human Cu/Zn superoxide dismutase: implication for gene dosage effects in Down syndrome. Cell 1988, 52:259-267.
32. Faizi M., Bader P.L., Tun C., Encarnacion A., Kleschevnikov A., Belichenko P., et al. Comprehensive behavioral phenotyping of Ts65Dn mouse model of Down syndrome: activation of beta1-adrenergic receptor by xamoterol as a potential cognitive enhancer. Neurobiol Dis 2011, 43:397-413.
33. Fernandez F., Morishita W., Zuniga E., Nguyen J., Blank M., Malenka R.C., et al. Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nat Neurosci 2007, 10:411-413.
34. Francis P.T. Altered glutamate neurotransmission and behaviour in dementia: evidence from studies of memantine. Curr Mol Pharmacol 2009, 2(1):77-82. [2009 Jan].
35. Freo U., Merico A., Ermani M., Ori C. Chronic treatment with fluoxetine decreases cerebral metabolic responses to the 5-HT1A agonist 8-hydroxy-2(di-N-propylamino)tetralin and increases those to the 5-HT2A/2C agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane and to the dopaminergic agonist apomorphine. Brain Res 2010, 1335:24-34.
36. Freund T.F., Buzsaki G. Interneurons of the hippocampus. Hippocampus 1996, 6:347-470.
37. Gedye A. Dietary increase in serotonin reduces self-injurious behaviour in a Down's syndrome adult. J Ment Defic Res 1990, 34(Pt 2):195-203.
38. Gedye A. Serotonergic treatment for aggression in a Down's syndrome adult showing signs of Alzheimer's disease. J Ment Defic Res 1991, 35(Pt 3):247-258.
39. Geldmacher D.S., Lerner A.J., Voci J.M., Noelker E.A., Somple L.C., Whitehouse P.J. Treatment of functional decline in adults with Down syndrome using selective serotonin-reuptake inhibitor drugs. J Geriatr Psychiatry Neurol 1997, 10:99-104.
40. Gonzalez Deniselle M.C., Garay L., Gonzalez S., Guennoun R., Schumacher M., De Nicola A.F. Progesterone restores retrograde labeling of cervical motoneurons in Wobbler mouse motoneuron disease. Exp Neurol 2005, 195:518-523.
41. Gulesserian T., Engidawork E., Cairns N., Lubec G. Increased protein levels of serotonin transporter in frontal cortex of patients with Down syndrome. Neurosci Lett 2000, 296:53-57.
42. Haier R.J1., Head K., Head E., Lott I.T. Neuroimaging of individuals with Down's syndrome at-risk for dementia: evidence for possible compensatory events. Neuroimage 2008, 39:1324-1332.
43. Hannon J., Hoyer D. Molecular biology of 5-HT receptors. Behav Brain Res 2008, 195:198-213.
44. Hanson J.E., Blank M., Valenzuela R.A., Garner C.C., Madison D.V. The functional nature of synaptic circuitry is altered in area CA3 of the hippocampus in a mouse model of Down's syndrome. J Physiol 2007, 579:53-67.
45. Harkany T., Abraham I., Timmerman W., Laskay G., Toth B., Sasvari M., et al. Beta-amyloid neurotoxicity is mediated by a glutamate-triggered excitotoxic cascade in rat nucleus basalis. Eur J Neurosci 2000, 12:2735-2745.
46. Hassold T., Hunt P. To err (meiotically) is human: the genesis of human aneuploidy. Nat Rev Genet 2001, 2:280-291.
47. Hattori M., Fujiyama A., Taylor T.D., Watanabe H., Yada T., Park H.S., et al. The DNA sequence of human chromosome 21. Nature 2000, 405:311-319.
48. Head E., Lott I.T., Patterson D., Doran E., Haier R.J. Possible compensatory events in adult Down syndrome brain prior to the development of Alzheimer disease neuropathology: targets for nonpharmacological intervention. J Alzheimers Dis 2007, 11:61-76.
49. Heinen M., Hettich M.M., Ryan D.P., Schnell S., Paesler K., Ehninger D. Adult-onset fluoxetine treatment does not improve behavioral impairments and may have adverse effects on the Ts65Dn mouse model of Down syndrome. Neural Plast 2012, 2012:467251.
50. Heller J.H., Spiridigliozzi G.A., Crissman B.G., McKillop J.A., Yamamoto H., Kishnani P.S. Safety and efficacy of rivastigmine in adolescents with Down syndrome: long-term follow-up. J Child Adolesc Psychopharmacol 2010, 20:517-520.
51. Heneka M.T., Ramanathan M., Jacobs A.H., Dumitrescu-Ozimek L., Bilkei-Gorzo A., Debeir T., et al. Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J Neurosci 2006, 26:1343-1354.
52. Hollander E., Rosen J. Impulsivity. J Psychopharmacol 2000, 14(2 Suppl 1):S39-44.
53. Hornung J.P. The human raphe nuclei and the serotonergic system. J Chem Neuroanat 2003, 26:331-343.
54. Ji J.Z., Zhang X.H., Li B.M. Deficient spatial memory induced by blockade of beta-adrenoceptors in the hippocampal CA1 region. Behav Neurosci 2003, 117:1378-1384.
55. Juric D.M., Miklic S., Carman-Krzan M. Monoaminergic neuronal activity up-regulates BDNF synthesis in cultured neonatal rat astrocytes. Brain Res 2006, 1108:54-62.
56. Kaufmann H. l-dihydroxyphenylserine (Droxidopa): a new therapy for neurogenic orthostatic hypotension: the US experience. Clin Auton Res 2008, 18(Suppl. 1):19-24. [2008 Mar].
57. Kaur G., Sharma A., Xu W., Gerum S., Alldred M.J., Subbanna S., et al. Glutamatergic transmission aberration: a major cause of behavioral deficits in a murine model of Down's syndrome. J Neurosci 2014, 34:5099-5106.
58. Kessels H.W., Nabavi S., Malinow R. Metabotropic NMDA receptor function is required for beta-amyloid-induced synaptic depression. Proc Natl Acad Sci U S A 2013, 110:4033-4038.
59. Kish S., Karlinsky H., Becker L., Gilbert J., Rebbetoy M., Chang L.J., et al. Down's syndrome individuals begin life with normal levels of brain cholinergic markers. J Neurochem 1989, 52:1183-1187.
60. Kishnani P.S., Heller J.H., Spiridigliozzi G.A., Lott I., Escobar L., Richardson S., et al. Donepezil for treatment of cognitive dysfunction in children with Down syndrome aged 10-17. Am J Med Genet A 2010, 152A:3028-3035.
61. Kleschevnikov A.M., Belichenko P.V., Villar A.J., Epstein C.J., Malenka R.C., Mobley W.C. Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome. J Neurosci 2004, 24:8153-8160.
62. Knust H., Achermann G., Ballard T., Buettelmann B., Gasser R., Fischer H., et al. The discovery and unique pharmacological profile of RO4938581 and RO4882224 as potent and selective GABAA alpha5 inverse agonists for the treatment of cognitive dysfunction. Bioorg Med Chem Lett 2009, 19:5940-5944.
63. Kurt M.A., Kafa M.I., Dierssen M., Davies D.C. Deficits of neuronal density in CA1 and synaptic density in the dentate gyrus, CA3 and CA1, in a mouse model of Down syndrome. Brain Res 2004, 1022:101-109.
64. Lee J.E., Giovannucci E., Fuchs C.S., Willett W.C., Zeisel S.H.., Cho E. Choline and betaine intake and the risk of colorectal cancer in men. Cancer Epidemiol Biomarkers Prev 2010, 19(3):884-887. [2010 Mar].
65. Li S., Jin M., Zhang D., Yang T., Koeglsperger T., Fu H., et al. Environmental novelty activates beta2-adrenergic signaling to prevent the impairment of hippocampal LTP by abeta oligomers. Neuron 2013, 77:929-941.
66. Lockrow J., Boger H., Bimonte-Nelson H., Granholm A.C. Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome. Behav Brain Res 2011, 221:610-622.
67. Mann D.M. The pathological association between Down syndrome and Alzheimer disease. Mech Ageing Dev 1988, 43:99-136.
68. Mann D.M., Yates P.O., Marcyniuk B., Ravindra C.R. Pathological evidence for neurotransmitter deficits in Down's syndrome of middle age. J Ment Defic Res 1985, 29(Pt 2):125-135. [1985 Jun].
69. Mann D.M., Yates P.O., Marcyniuk B., Ravindra C.R. The topography of plaques and tangles in Down's syndrome patients of different ages. Neuropathol Appl Neurobiol 1986, 12(5):447-457. [1986 Sep-Oct].
70. Masuda T., Nakagawa S., Boku S., Nishikawa H., Takamura N., Kato A., et al. Noradrenaline increases neural precursor cells derived from adult rat dentate gyrus through beta2 receptor. Prog Neuropsychopharmacol Biol Psychiatry 2012, 36:44-51.
71. Millan M.J. An epigenetic framework for neurodevelopmental disorders: from pathogenesis to potential therapy. Neuropharmacology 2013, 68:2-82.
72. Millan Sanchez M., Heyn S.N., Das D., Moghadam S., Martin K.J., Salehi A. Neurobiological elements of cognitive dysfunction in down syndrome: exploring the role of APP. Biol Psychiatry 2012, 71(5):403-409.
73. Mohan M., Bennett C., Carpenter P.K. Memantine for dementia in people with Down syndrome. Cochrane Database Syst Rev 2009, CD007657.
74. Nagahara A.H., Merrill D.A., Coppola G., Tsukada S., Schroeder B.E., Shaked G.M., et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med 2009, 15:331-337.
75. O'Doherty A., Ruf S., Mulligan C., Hildreth V., Errington M.L., Cooke S., et al. An aneuploid mouse strain carrying human chromosome 21 with Down syndrome phenotypes. Science 2005, 309:2033-2037.
76. Olson L.E., Richtsmeier J.T., Leszl J., Reeves R.H. A chromosome 21 critical region does not cause specific Down syndrome phenotypes. Science 2004, 306:687-690.
77. Palop J.J., Mucke L. Epilepsy and cognitive impairments in Alzheimer disease. Arch Neurol 2009, 66:435-440.
78. Park H.J., Friston K. Structural and functional brain networks: from connections to cognition. Nature 2013, 342:6158.
79. Parsons C.G., Gruner R., Rozental J., Millar J., Lodge D. Patch clamp studies on the kinetics and selectivity of N-methyl-d-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan). Neuropharmacology 1993, 32:1337-1350.
80. Paula-Lima A.C., Louzada P.R., De Mello F.G., Ferreira S.T. Neuroprotection against Abeta and glutamate toxicity by melatonin: are GABA receptors involved?. Neurotox Res 2003, 5:323-327.
81. Pauwels, Lofdahl, Postma, Tattersfield, O'Bryne, Barnes, et al. The effect of inhaled formoterol and budesonide on exacerbatins of asthma. N Engl J Med 1997, 337:1405-1411.
82. Prasher V.P. Seizures associated with fluoxetine therapy. Seizure 1993, 2:315-317.
83. Prasher V.P., Farrer M.J., Kessling A.M., Fisher E.M., West R.J., Barber P.C., et al. Molecular mapping of Alzheimer-type dementia in Down's syndrome. Ann Neurol 1998, 43(3):380-383.
84. Prasher V.P., Huxley A., Haque M.S. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease - pilot study. Int J Geriatr Psychiatry 2002, 17:270-278.
85. Prasher V.P., Sachdeva N., Adams C., Haque M.S. Rivastigmine transdermal patches in the treatment of dementia in Alzheimer's disease in adults with Down syndrome-pilot study. Int J Geriatr Psychiatry 2013, 28:219-220.
86. Presson A.P., Partyka G., Jensen K.M., Devine O.J., Rasmussen S.A., McCabe L.L., et al. Current estimate of Down syndrome population prevalence in the United States 2013, 164:1163-1168.
87. Rissman R.A., Mobley W.C. Implications for treatment: GABAA receptors in aging, Down syndrome and Alzheimer's disease. J Neurochem 2011, 117:613-622.
88. Rueda N., Florez J., Martinez-Cue C. Chronic pentylenetetrazole but not donepezil treatment rescues spatial cognition in Ts65Dn mice, a model for Down syndrome. Neurosci Lett 2008, 433:22-27.
89. Rueda N., Llorens-Martin M., Florez J., Valdizan E., Banerjee P., Trejo J.L., et al. Memantine normalizes several phenotypic features in the Ts65Dn mouse model of Down syndrome. J Alzheimers Dis 2010, 21:277-290.
90. Rueda N., Flórez J., Martínez-Cué C. Mouse models of Down syndrome as a tool to unravel the causes of mental disabilities. Neural Plast 2012, 2012.
91. Sago H., Carlson E.J., Smith D.J., Kilbridge J., Rubin E.M., Mobley W.C., et al. Ts1Cje, a partial trisomy 16 mouse model for Down syndrome, exhibits learning and behavioral abnormalities. Proc Natl Acad Sci U S A 1998, 95:6256-6261.
92. Salehi A., Lucassen P.J., Pool C.W., Gonatas N.K., Ravid R., Swaab D.F. Decreased neuronal activity in the nucleus basalis of Meynert in Alzheimer's disease as suggested by the size of the Golgi apparatus. Neuroscience 1994, 59:871-880.
93. Salehi A., Delcroix J.D., Swaab D.F. Alzheimer's disease and NGF signaling. J Neural Transm 2004, 111:323-345.
94. Salehi A., Delcroix J.-D., Belichenko P.V., Zhan K., Wu C., Valletta J.S., et al. Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron 2006, 51:29-42.
95. Salehi A., Faizi M., Belichenko P.V., Mobley W.C. Using mouse models to explore genotype-phenotype relationship in Down syndrome. Ment Retard Dev Disabil Res Rev 2007, 13:207-214.
96. Salehi A., Faizi M., Colas D., Valletta J., Laguna J., Takimoto-Kimura R., et al. Restoration of norepinephrine-modulated contextual memory in a mouse model of Down syndrome. Sci Transl Med 2009, 1:7ra17.
97. Sanchez M.M., Moghadam S., Naik P., Martin K.J., Salehi A. Hippocampal network alterations in Alzheimer's disease and Down syndrome: from structure to therapy. J Alzheimers Dis 2011, 26(Suppl 3):29-47.
98. Sara S.J. The locus coeruleus and noradrenergic modulation of cognition. Nat Rev Neurosci 2009, 10:211-223.
99. Schliebs R1., Arendt T. The cholinergic system in aging and neuronal degeneration. Behav Brain Res 2011, 221(2):555-563. [2011 Aug 10].
100. Schneider L.S., Dagerman K.S., Higgins J.P., McShane R. Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch Neurol 2011, 68:991-998.
101. Siarey R.J., Carlson E.J., Epstein C.J., Balbo A., Rapoport S.I., Galdzicki Z. Increased synaptic depression in the Ts65Dn mouse, a model for mental retardation in Down syndrome. Neuropharmacology 1999, 38:1917-1920.
102. Siddiqui A., Lacroix T., Stasko M.R., Scott-McKean J.J., Costa A.C., Gardiner K.J. Molecular responses of the Ts65Dn and Ts1Cje mouse models of Down syndrome to MK-801. Genes Brain Behav 2008, 7:810-820.
103. Sofroniew M.V., Howe C.L., Mobley W.C. Nerve growth factor signaling, neuroprotection, and neural repair. Annu Rev Neurosci 2001, 24:1217-1281.
104. Stagni F., Magistretti J., Guidi S., Ciani E., Mangano C., Calza L., et al. Pharmacotherapy with fluoxetine restores functional connectivity from the dentate gyrus to field CA3 in the Ts65Dn mouse model of Down syndrome. PLoS One 2013, 8:e61689.
105. Trillo L., Das D., Hsieh W., Medina B., Moghadam S., Lin B., et al. Ascending monoaminergic systems alterations in Alzheimer's disease; translating basic science into clinical care. Neurosci Biobehav Rev 2013, 37(8):1363-1379.
106. Tuszynski M.H., Thal L., Pay M., Salmon D.P., HS U., Bakay R., et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 2005, 11(5):551-555. [2005 May].
107. Van Dam D., De Deyn P.P. Cognitive evaluation of disease-modifying efficacy of galantamine and memantine in the APP23 model. Eur Neuropsychopharmacol 2006, 16:59-69.
108. Velazquez R., Ash J.A., Powers B.E., Kelley C.M., Strawderman M., Luscher Z.I., et al. Maternal choline supplementation improves spatial learning and adult hippocampal neurogenesis in the Ts65Dn mouse model of Down syndrome. Neurobiol Dis 2013, 58:92-101.
109. Wang L.Y1., Shofer J.B., Rohde K., Hart K.L., Hoff D.J., McFall Y.H., et al. Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression. Am J Geriatr Psychiatry 2009, 17(9):744-751. [2009 Sep].
110. White N.S., Alkire M.T., Haier R.J. A voxel-based morphometric study of nondemented adults with Down syndrome. Neuroimage 2003, 20:393-403.
111. Whittle N., Sartori S.B., Dierssen M., Lubec G., Singewald N. Fetal Down syndrome brains exhibit aberrant levels of neurotransmitters critical for normal brain development. Pediatrics 2007, 120:e1465-e1471.
112. Wilcock D.M., Griffin W.S. Down's syndrome, neuroinflammation, and Alzheimer neuropathogenesis. J Neuroinflammation 2013, 16:10-84.
113. Yamada K., Takayanagi M., Kamei H., Nagai T., Dohniwa M., Kobayashi K., et al. Effects of memantine and donepezil on amyloid beta-induced memory impairment in a delayed-matching to position task in rats. Behav Brain Res 2005, 162:191-199.
114. Yu T., Li Z., Jia Z., Clapcote S.J., Liu C., Li S., et al. A mouse model of Down syndrome trisomic for all human chromosome 21 syntenic regions. Hum Mol Genet 2010, 19:2780-2791.